SVVYGLR motif of the thrombin-cleaved N-terminal osteopontin fragment enhances the synthesis of collagen type III in myocardial fibrosis

Mol Cell Biochem. 2015 Oct;408(1-2):191-203. doi: 10.1007/s11010-015-2495-y. Epub 2015 Jun 27.

Abstract

Osteopontin (OPN) is involved in various physiological processes such as inflammatory and wound healing. However, little is known about the effects of OPN on these tissues. OPN is cleaved by thrombin, and cleavage of the N-terminal fragment exposes a SVVYGLR sequence on its C-terminus. In this study, we examined the effects of the thrombin-cleaved OPN fragments on fibroblasts and myocardial fibrosis, particularly the role of the SVVYGLR sequence. The recombinant thrombin-cleaved OPN fragments (N-terminal fragment [N-OPN], C-terminal fragment [C-OPN], and the N-terminal fragment lacking the SVVYGLR sequence [ΔSV N-OPN]) were added to fibroblasts, and the cellular motility, signal activity, and production of collagen were evaluated. A sustained-release gel containing an OPN fragment or SVVYGLR peptide was transplanted into a rat model of ischemic cardiomyopathy and the quantities and ratio of collagen type I (COL I) and type III (COL III) were estimated. N-OPN significantly promoted fibroblast migration. Smad signal activity, expression of smooth muscle actin (SMA), and the production of COL III were enhanced by N-OPN and SVVYGLR peptide. Conversely, ΔSV N-OPN and C-OPN had no effect. In vivo, the expression level of N-OPN was associated with COL III distribution, and the COL III/COL I ratio was significantly increased by the sustained-release gel containing N-OPN or SVVYGLR peptide. The cardiac function was also significantly improved by the N-OPN- or SVVYGLR peptide-released gel treatment. The N-terminal fragment of thrombin-cleaved OPN-induced Smad signal activation, SMA expression, and COL III production, and its SVVYGLR sequence influences this function.

Keywords: Collagen type III; Fibrosis; Osteopontin; SVVYGLR peptide.

MeSH terms

  • Animals
  • Cardiomyopathies / drug therapy*
  • Cardiomyopathies / physiopathology
  • Cell Line
  • Cell Movement / drug effects
  • Collagen Type III / metabolism*
  • Delayed-Action Preparations
  • Fibroblasts / cytology
  • Fibroblasts / drug effects*
  • Fibroblasts / metabolism
  • Humans
  • Myocardium / cytology
  • Myocardium / metabolism
  • Myocardium / pathology*
  • Oligopeptides / administration & dosage*
  • Oligopeptides / pharmacology
  • Osteopontin / chemistry
  • Osteopontin / metabolism
  • Protein Structure, Tertiary
  • Rats
  • Signal Transduction / drug effects
  • Skin / cytology*
  • Skin / metabolism
  • Thrombin / metabolism

Substances

  • Collagen Type III
  • Delayed-Action Preparations
  • Oligopeptides
  • SVVYGLR peptide
  • Osteopontin
  • Thrombin